Vascular phenotypes in primary non-small cell lung carcinomas and matched brain metastases

A. M. Jubb, A. Cesario, M. Ferguson, M. T. Congedo, K. C. Gatter, F. Lococo, A. Mulè, F. Pezzella

Research output: Contribution to journalArticle

30 Citations (Scopus)

Abstract

Background:Anti-angiogenic therapy with bevacizumab (an anti-vascular endothelial growth factor (VEGF) antibody) predominantly targets immature blood vessels. Bevacizumab has shown a survival benefit in non-small cell lung carcinoma (NSCLC) and has recently been demonstrated to be safe in patients with brain metastases. However, it is not known whether bevacizumab is effective against brain metastases or whether metastases are representative of their primary in terms of VEGF expression, hypoxia, proliferation and vascular phenotype. The aim of this study was to evaluate these factors in a series of matched primary NSCLCs and brain metastases.Methods and Results: Immunohistochemistry showed strong correlation of carbonic anhydrase 9 expression (a marker of hypoxia) in primary and secondary cancers (P0.0002). However, the proliferation index, VEGF expression, microvessel density and the proportion of mature vessels were discordant between primary and secondary cancers. The mean proportion of mature vessels was 63.2% higher in the brain metastases than the primary tumours (P0.004). Moreover, the vascular pattern of the primary tumour was not representative of the metastasis.Conclusions:Brain metastases have a significantly higher proportion of mature vasculature, suggesting that they may be refractory to anti-VEGF therapy. These findings may have implications for clinical trials and biomarker studies evaluating anti-angiogenic agents in brain metastases.

Original languageEnglish
Pages (from-to)1877-1881
Number of pages5
JournalBritish Journal of Cancer
Volume104
Issue number12
DOIs
Publication statusPublished - Jun 7 2011

Fingerprint

Non-Small Cell Lung Carcinoma
Blood Vessels
Neoplasm Metastasis
Phenotype
Brain
Vascular Endothelial Growth Factor A
Neoplasms
Microvessels
Brain Neoplasms
Biomarkers
Immunohistochemistry
Clinical Trials
Survival
Antibodies
Therapeutics
Bevacizumab

Keywords

  • angiogenesis
  • brain
  • metastases
  • non-small cell lung carcinoma
  • vascular

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Vascular phenotypes in primary non-small cell lung carcinomas and matched brain metastases. / Jubb, A. M.; Cesario, A.; Ferguson, M.; Congedo, M. T.; Gatter, K. C.; Lococo, F.; Mulè, A.; Pezzella, F.

In: British Journal of Cancer, Vol. 104, No. 12, 07.06.2011, p. 1877-1881.

Research output: Contribution to journalArticle

Jubb, AM, Cesario, A, Ferguson, M, Congedo, MT, Gatter, KC, Lococo, F, Mulè, A & Pezzella, F 2011, 'Vascular phenotypes in primary non-small cell lung carcinomas and matched brain metastases', British Journal of Cancer, vol. 104, no. 12, pp. 1877-1881. https://doi.org/10.1038/bjc.2011.147
Jubb, A. M. ; Cesario, A. ; Ferguson, M. ; Congedo, M. T. ; Gatter, K. C. ; Lococo, F. ; Mulè, A. ; Pezzella, F. / Vascular phenotypes in primary non-small cell lung carcinomas and matched brain metastases. In: British Journal of Cancer. 2011 ; Vol. 104, No. 12. pp. 1877-1881.
@article{8c19e783749b472a8a9450d0ee6f8c35,
title = "Vascular phenotypes in primary non-small cell lung carcinomas and matched brain metastases",
abstract = "Background:Anti-angiogenic therapy with bevacizumab (an anti-vascular endothelial growth factor (VEGF) antibody) predominantly targets immature blood vessels. Bevacizumab has shown a survival benefit in non-small cell lung carcinoma (NSCLC) and has recently been demonstrated to be safe in patients with brain metastases. However, it is not known whether bevacizumab is effective against brain metastases or whether metastases are representative of their primary in terms of VEGF expression, hypoxia, proliferation and vascular phenotype. The aim of this study was to evaluate these factors in a series of matched primary NSCLCs and brain metastases.Methods and Results: Immunohistochemistry showed strong correlation of carbonic anhydrase 9 expression (a marker of hypoxia) in primary and secondary cancers (P0.0002). However, the proliferation index, VEGF expression, microvessel density and the proportion of mature vessels were discordant between primary and secondary cancers. The mean proportion of mature vessels was 63.2{\%} higher in the brain metastases than the primary tumours (P0.004). Moreover, the vascular pattern of the primary tumour was not representative of the metastasis.Conclusions:Brain metastases have a significantly higher proportion of mature vasculature, suggesting that they may be refractory to anti-VEGF therapy. These findings may have implications for clinical trials and biomarker studies evaluating anti-angiogenic agents in brain metastases.",
keywords = "angiogenesis, brain, metastases, non-small cell lung carcinoma, vascular",
author = "Jubb, {A. M.} and A. Cesario and M. Ferguson and Congedo, {M. T.} and Gatter, {K. C.} and F. Lococo and A. Mul{\`e} and F. Pezzella",
year = "2011",
month = "6",
day = "7",
doi = "10.1038/bjc.2011.147",
language = "English",
volume = "104",
pages = "1877--1881",
journal = "British Journal of Cancer",
issn = "0007-0920",
publisher = "Nature Publishing Group",
number = "12",

}

TY - JOUR

T1 - Vascular phenotypes in primary non-small cell lung carcinomas and matched brain metastases

AU - Jubb, A. M.

AU - Cesario, A.

AU - Ferguson, M.

AU - Congedo, M. T.

AU - Gatter, K. C.

AU - Lococo, F.

AU - Mulè, A.

AU - Pezzella, F.

PY - 2011/6/7

Y1 - 2011/6/7

N2 - Background:Anti-angiogenic therapy with bevacizumab (an anti-vascular endothelial growth factor (VEGF) antibody) predominantly targets immature blood vessels. Bevacizumab has shown a survival benefit in non-small cell lung carcinoma (NSCLC) and has recently been demonstrated to be safe in patients with brain metastases. However, it is not known whether bevacizumab is effective against brain metastases or whether metastases are representative of their primary in terms of VEGF expression, hypoxia, proliferation and vascular phenotype. The aim of this study was to evaluate these factors in a series of matched primary NSCLCs and brain metastases.Methods and Results: Immunohistochemistry showed strong correlation of carbonic anhydrase 9 expression (a marker of hypoxia) in primary and secondary cancers (P0.0002). However, the proliferation index, VEGF expression, microvessel density and the proportion of mature vessels were discordant between primary and secondary cancers. The mean proportion of mature vessels was 63.2% higher in the brain metastases than the primary tumours (P0.004). Moreover, the vascular pattern of the primary tumour was not representative of the metastasis.Conclusions:Brain metastases have a significantly higher proportion of mature vasculature, suggesting that they may be refractory to anti-VEGF therapy. These findings may have implications for clinical trials and biomarker studies evaluating anti-angiogenic agents in brain metastases.

AB - Background:Anti-angiogenic therapy with bevacizumab (an anti-vascular endothelial growth factor (VEGF) antibody) predominantly targets immature blood vessels. Bevacizumab has shown a survival benefit in non-small cell lung carcinoma (NSCLC) and has recently been demonstrated to be safe in patients with brain metastases. However, it is not known whether bevacizumab is effective against brain metastases or whether metastases are representative of their primary in terms of VEGF expression, hypoxia, proliferation and vascular phenotype. The aim of this study was to evaluate these factors in a series of matched primary NSCLCs and brain metastases.Methods and Results: Immunohistochemistry showed strong correlation of carbonic anhydrase 9 expression (a marker of hypoxia) in primary and secondary cancers (P0.0002). However, the proliferation index, VEGF expression, microvessel density and the proportion of mature vessels were discordant between primary and secondary cancers. The mean proportion of mature vessels was 63.2% higher in the brain metastases than the primary tumours (P0.004). Moreover, the vascular pattern of the primary tumour was not representative of the metastasis.Conclusions:Brain metastases have a significantly higher proportion of mature vasculature, suggesting that they may be refractory to anti-VEGF therapy. These findings may have implications for clinical trials and biomarker studies evaluating anti-angiogenic agents in brain metastases.

KW - angiogenesis

KW - brain

KW - metastases

KW - non-small cell lung carcinoma

KW - vascular

UR - http://www.scopus.com/inward/record.url?scp=79958148848&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79958148848&partnerID=8YFLogxK

U2 - 10.1038/bjc.2011.147

DO - 10.1038/bjc.2011.147

M3 - Article

C2 - 21540863

AN - SCOPUS:79958148848

VL - 104

SP - 1877

EP - 1881

JO - British Journal of Cancer

JF - British Journal of Cancer

SN - 0007-0920

IS - 12

ER -